Furthermore, patients can experience differential responses for their different psoriatic disease manifestations, an example being that therapies targeting the IL-17 pathway can result in dramatic psoriasis responses while improvement in peripheral arthritis may not be as impressive. This evidence concerns the gene IL17A and psoriasis.